Meridian Bioscience Inc. (VIVO)
Company Description
Meridian Bioscience, Inc., a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide.
The company operates through Diagnostics and Life Science segments.
The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H. pylori under the BreathID and BreathTek brand.
This segment also offers respiratory illness assays, such as tests Group A strep, mycoplasma pneumonia, influenza, and pertussis; and blood chemistry products for LeadCare test kits for the detection of lead in blood.
It sells products through direct sales force and independent distributors to acute care hospitals, reference laboratories, outpatient clinics, and physician office laboratories.
The Life Science segment offers bulk antigens, antibodies, PCR/qPCR reagents, nucleotides, and bioresearch reagents used by in vitro diagnostic manufacturers, as well as researchers in immunological and molecular tests for human, animal, plant, and environmental applications.
Meridian Bioscience, Inc. was incorporated in 1976 and is headquartered in Cincinnati, Ohio.

Country | United States |
IPO Date | Jul 29, 1986 |
Industry | Medical - Diagnostics & Research |
Sector | Healthcare |
Employees | 690 |
CEO | John P. Kenny |
Contact Details
Address: 3471 River Hills Drive Cincinnati, Ohio United States | |
Website | https://www.meridianbioscience.com |
Stock Details
Ticker Symbol | VIVO |
Exchange | NASDAQ |
Fiscal Year | October - September |
Reporting Currency | USD |
CIK Code | 0000794172 |
CUSIP Number | 589584101 |
ISIN Number | US5895841014 |
Employer ID | 31-0888197 |
SIC Code | 2835 |
Key Executives
Name | Position |
---|---|
John P. Kenny | Pres, Chief Executive Officer & Director |
Andrew S. Kitzmiller | Executive Vice President & Chief Financial Officer |
Charles Wood | Vice President of Corporation Strategy, Bus. Devel. & Investor Relations |
Dr. Lourdes G. Weltzien Ph.D. | Executive Vice President of Life Science Bus. Unit |
Emerson C. Moser | Senior Vice President & Gen. Counsel |
Jeff Pinkston | Director of Corporation Fin. |
Julie Smith | Senior Vice President, Controller & Principal Accounting Officer |
Melissa A. Lueke | Consultant |
Melissa J. McCarey | Vice President of Global HR |
Susan D. Rolih | Consultant |
Tony Serafini-Lamanna | Executive Vice President of Diagnostics |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 13, 2023 | 15-12G | Filing |
Feb 09, 2023 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
Feb 09, 2023 | 10-Q | Quarterly Report |
Feb 03, 2023 | SC 13D/A | [Amend] Filing |
Feb 02, 2023 | S-8 POS | Filing |
Feb 02, 2023 | S-8 POS | Filing |
Feb 02, 2023 | S-8 POS | Filing |
Feb 02, 2023 | S-8 POS | Filing |
Feb 02, 2023 | S-8 POS | Filing |
Feb 02, 2023 | S-8 POS | Filing |